Limits...
Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus

Mean intraocular pressure with latanoprost, travoprost, and bimatoprost at baseline and after 12 weeks of treatment in a cohort of primary open-angle glaucoma and ocular hypertension patients.Note: Reprinted from Am J Ophthalmol. 135(5):688–703. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Copyright 2003 with permission from Elsevier.56
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401333&req=5

f3-opth-9-633: Mean intraocular pressure with latanoprost, travoprost, and bimatoprost at baseline and after 12 weeks of treatment in a cohort of primary open-angle glaucoma and ocular hypertension patients.Note: Reprinted from Am J Ophthalmol. 135(5):688–703. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Copyright 2003 with permission from Elsevier.56

Mentions: Parrish et al compared latanoprost, travoprost, and bimatoprost in a head-to-head randomized 12-week prospective trial, including 410 patients affected by POAG and OHT.56 Mean IOP at baseline was similar among the three groups (latanoprost: 25.7 mmHg, bimatoprost: 25.7 mmHg, and travoprost: 25.5 mmHg). Adjusted IOP reductions in mean IOP at 8 am were similar (P=0.12), as were those at 12 pm, 4 pm, and 8 pm. The estimated 8 am IOP reduction at 12 weeks was 8.6±0.3 mmHg for latanoprost, 8.7±0.3 mmHg for bimatoprost, and 8.0±0.3 mmHg for travoprost (Figure 3).


Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Mean intraocular pressure with latanoprost, travoprost, and bimatoprost at baseline and after 12 weeks of treatment in a cohort of primary open-angle glaucoma and ocular hypertension patients.Note: Reprinted from Am J Ophthalmol. 135(5):688–703. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Copyright 2003 with permission from Elsevier.56
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401333&req=5

f3-opth-9-633: Mean intraocular pressure with latanoprost, travoprost, and bimatoprost at baseline and after 12 weeks of treatment in a cohort of primary open-angle glaucoma and ocular hypertension patients.Note: Reprinted from Am J Ophthalmol. 135(5):688–703. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Copyright 2003 with permission from Elsevier.56
Mentions: Parrish et al compared latanoprost, travoprost, and bimatoprost in a head-to-head randomized 12-week prospective trial, including 410 patients affected by POAG and OHT.56 Mean IOP at baseline was similar among the three groups (latanoprost: 25.7 mmHg, bimatoprost: 25.7 mmHg, and travoprost: 25.5 mmHg). Adjusted IOP reductions in mean IOP at 8 am were similar (P=0.12), as were those at 12 pm, 4 pm, and 8 pm. The estimated 8 am IOP reduction at 12 weeks was 8.6±0.3 mmHg for latanoprost, 8.7±0.3 mmHg for bimatoprost, and 8.0±0.3 mmHg for travoprost (Figure 3).

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus